Baseline patient demographics, procedural details, pharmacology and outcomes
| Clopidogrel (58 248) | Prasugrel (17 714) | Ticagrelor (13 105) | P value* | P value† | |
| Age | 64.0 (54.0–75.0) | 61.0 (52.0–69.0) | 63.0 (53.0–72.0) | <0.0001 | <0.0001 |
| Gender (male) | 42 821 (73.5%) | 13 739 (77.6%) | 9721 (74.2%) | <0.0001 | <0.0001 |
| Smoking status | <0.0001 | <0.0001 | |||
| Never | 16 934 (32.3%) | 4797 (29.6%) | 4545 (37.6%) | ||
| Ex-smoker | 15 465 (29.5%) | 4021 (24.8%) | 2742 (22.7%) | ||
| Current | 20 033 (38.2%) | 7384 (45.6%) | 4785 (39.6%) | ||
| Diabetes | 8233 (14.8%) | 2315 (13.4%) | 1927 (15.0%) | <0.0001 | <0.0001 |
| History of peripheral vascular disease | 2024 (3.6%) | 416 (2.5%) | 332 (2.7%) | <0.0001 | 0.21 |
| Hypertension | 25 022 (44.9%) | 6363 (37.5%) | 4986 (40.5%) | <0.0001 | <0.0001 |
| Hypercholesterolaemia | 23 246 (41.7%) | 6850 (40.4%) | 4630 (37.6%) | <0.0001 | <0.0001 |
| History of renal disease | 478 (0.9%) | 67 (0.4%) | 42 (0.3%) | <0.0001 | 0.34 |
| History of coronary artery bypass graft | 1866 (4.7%) | 356 (2.5%) | 367 (4.2%) | <0.0001 | <0.0001 |
| History myocardial infarction | 7603 (14.0%) | 1866 (10.7%) | 1472 (12.3%) | <0.0001 | <0.0001 |
| History of stroke | 2368 (4.2%) | 322 (1.9%) | 411 (3.3%) | <0.0001 | <0.0001 |
| History of percutaneous coronary intervention | 5642 (9.9%) | 1458 (8.3%) | 1120 (8.7%) | <0.0001 | 0.22 |
| Left ventricular ejection fraction | <0.0001 | <0.0001 | |||
| Good (>50%) | 10 098 (52.1%) | 2764 (55.8%) | 1978 (51.1%) | ||
| Moderate (30%–50%) | 7117 (36.7%) | 1763 (35.6%) | 1532 (39.6%) | ||
| Poor (<30%) | 2181 (11.2%) | 427 (8.6%) | 363 (9.4%) | ||
| TIMI flow | <0.0001 | <0.0001 | |||
| TIMI 0 | 35 718 (69.2%) | 12 239 (75.8%) | 8140 (71.6%) | ||
| TIMI 1 | 4660 (9.0%) | 1057 (6.5%) | 964 (8.5%) | ||
| TIMI 2 | 5031 (9.8%) | 1502 (9.3%) | 1101 (9.7%) | ||
| TIMI 3 | 6189 (12.0%) | 1341 (8.3%) | 1161 (10.2%) | ||
| Access site (radial) | 26 514 (47.1%) | 12 692 (74.9%) | 9765 (78.3%) | <0.0001 | <0.0001 |
| Stent | <0.0001 | <0.0001 | |||
| None | 4422 (8.0%) | 1050 (6.1%) | 773 (6.1%) | ||
| Bare metal | 19 479 (35.2%) | 4217 (24.5%) | 1503 (11.9%) | ||
| Drug eluting | 31 492 (56.9%) | 11 974 (69.5%) | 10 381 (82.0%) | ||
| Vessel attempted | <0.0001 | <0.0001 | |||
| Venous or arterial graft | 803 (1.4%) | 259 (1.5%) | 143 (1.1%) | ||
| Left main stem artery | 411 (0.7%) | 67 (0.4%) | 230 (1.8%) | ||
| Left anterior descending artery | 22 858 (39.5%) | 6905 (39.2%) | 4974 (38.2%) | ||
| Left circumflex artery | 7216 (12.5%) | 2186 (12.4%) | 1839 (14.1%) | ||
| Right coronary artery | 22 915 (39.6%) | 7269 (41.2%) | 5147 (39.5%) | ||
| Multiple | 3671 (6.3%) | 937 (5.3%) | 700 (5.4%) | ||
| Cardiogenic shock | 4155 (7.2%) | 988 (5.6%) | 812 (6.2%) | <0.0001 | 0.020 |
| Intra-aortic balloon pump use | 2832 (5.1%) | 567 (3.4%) | 421 (3.4%) | <0.0001 | 0.77 |
| Ventilatory support | 1891 (3.5%) | 425 (2.5%) | 392 (3.4%) | <0.0001 | <0.0001 |
| Thrombectomy | 25 933 (46.6%) | 8583 (51.0%) | 6518 (52.7%) | <0.0001 | 0.005 |
| Bivalirudin use | 5095 (8.7%) | 5697 (32.2%) | 2963 (22.6%) | <0.0001 | <0.0001 |
| Glycoprotein IIb/IIIa inhibitor use | 30 258 (53.7%) | 7672 (44.5%) | 4294 (34.8%) | <0.0001 | <0.0001 |
| Year | <0.0001 | <0.0001 | |||
| 2007 | 3448 (5.9%) | 0 (0.0%) | 0 (0.0%) | ||
| 2008 | 5467 (9.4%) | 0 (0.0%) | 0 (0.0%) | ||
| 2009 | 8134 (14.0%) | 42 (0.2%) | 0 (0.0%) | ||
| 2010 | 9491 (16.3%) | 1649 (9.3%) | 4 (0.0%) | ||
| 2011 | 9204 (15.8%) | 4383 (24.7%) | 15 (0.1%) | ||
| 2012 | 8528 (14.6%) | 5049 (28.5%) | 1601 (12.2%) | ||
| 2013 | 7408 (12.7%) | 3594 (20.3%) | 4870 (37.2%) | ||
| 2014 | 6568 (11.3%) | 2997 (16.9%) | 6615 (50.5%) | ||
| Bleeding | 843 (1.5%) | 121 (0.7%) | 76 (0.6%) | <0.0001 | 0.30 |
| Major adverse cardiovascular event | 2783 (4.9%) | 545 (3.2%) | 616 (4.8%) | <0.0001 | <0.0001 |
| 30-Day mortality | 3534 (6.4%) | 622 (3.6%) | 689 (5.5%) | <0.0001 | <0.0001 |
| 1-Year mortality | 5656 (10.2%) | 999 (5.9%) | 1075 (8.5%) | <0.0001 | <0.0001 |
*Resulting tests when comparing the three groups.
†Resulting tests when comparing ticagrelor vs prasugrel only.